Margaret A. Goodell

Margaret A. Goodell

Top Cited Scholar 2025
Auto-generated profile, based on publicly available information

Margaret A. Goodell

Baylor College of Medicine

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 1996 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
MGM A Goodell
M A Goodell
KBK Brose
K Brose
GPG Paradis
G Paradis
ACA S Conner
A S Conner
RMR C Mulligan
R C Mulligan
Hematopoietic stem cells (HSC) are multipotent cells that reside in the bone marrow and replenish all adult hematopoietic lineages throughout the lifetime of the animal. While experimenting with staining of murine bone marrow cells with the vital dye, Hoechst 33342, we discovered that display of Hoechst fluorescence simultaneously at two emission wavelengths revealed a small and distinct subset of whole bone marrow cells that had phenotypic markers of multipotential HSC. These cells were shown in competitive repopulation experiments to contain the vast majority of HSC activity from murine bone marrow and to be enriched at least 1,000-fold for in vivo reconstitution activity. Further, these Hoechst-stained side population (SP) cells were shown to protect recipients from lethal irradiation at low cell doses, and to contribute to both lymphoid and myeloid lineages. The formation of the Hoechst SP profile was blocked when staining was performed in the presence of verapamil, indicating that the distinctly low staining pattern of the SP cells is due to a multidrug resistance protein (mdr) or mdr-like mediated efflux of the dye from HSC. The ability to block the Hoechst efflux activity also allowed us to use Hoechst to determine the DNA content of the SP cells. Between 1 and 3% of the HSC were shown to be in S-G2M. This also enabled the purification of the G0-G1 and S-G2M HSC had a reconstitution capacity equivalent to quiescent stem cells. These findings have implications for models of hematopoietic cell development and for the development of genetic therapies for diseases involving hematopoietic cells.

1 June 2001 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
KJKathyjo A. Jackson
Kathyjo A. Jackson
SMSusan M. Majka
Susan M. Majka
HWHongyu Wang
Hongyu Wang
JPJennifer Pocius
Jennifer Pocius
CHCraig J. Hartley
Craig J. Hartley
MGMargaret A. Goodell
Margaret A. Goodell
Myocyte loss in the ischemically injured mammalian heart often leads to irreversible deficits in cardiac function. To identify a source of stem cells capable of restoring damaged cardiac tissue, we transplanted highly enriched hematopoietic stem cells, the so-called side population (SP) cells, into lethally irradiated mice subsequently rendered ischemic by coronary artery occlusion for 60 minutes followed by reperfusion. The engrafted SP cells (CD34–/low, c-Kit+, Sca-1+) or their progeny migrated into ischemic cardiac muscle and blood vessels, differentiated to cardiomyocytes and endothelial cells, and contributed to the formation of functional tissue. SP cells were purified from Rosa26 transgenic mice, which express lacZ widely. Donor-derived cardiomyocytes were found primarily in the peri-infarct region at a prevalence of around 0.02% and were identified by expression of lacZ and α-actinin, and lack of expression of CD45. Donor-derived endothelial cells were identified by expression of lacZ and Flt-1, an endothelial marker shown to be absent on SP cells. Endothelial engraftment was found at a prevalence of around 3.3%, primarily in small vessels adjacent to the infarct. Our results demonstrate the cardiomyogenic potential of hematopoietic stem cells and suggest a therapeutic strategy that eventually could benefit patients with myocardial infarction.

1 September 1992 in Nature
Verified
Journal Article
Closed access
TJTyler Jacks
Tyler Jacks
AFAmin Fazeli
Amin Fazeli
ESEarlene M. Schmitt
Earlene M. Schmitt
RBRoderick T. Bronson
Roderick T. Bronson
MGMargaret A. Goodell
Margaret A. Goodell
RWRobert A. Weinberg
Robert A. Weinberg

4 December 2011 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
GCGrant A Challen
Grant A Challen
DSdeqiang sun
deqiang sun
MJMira Jeong
Mira Jeong
MLMin Luo
Min Luo
JJJaroslav Jelinek
Jaroslav Jelinek
MGMargaret A Goodell
Margaret A Goodell

20 September 2004 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
CHC. Hirschmann-Jax
C. Hirschmann-Jax
AFA. E. Foster
A. E. Foster
GWG. G. Wulf
G. G. Wulf
JNJ. G. Nuchtern
J. G. Nuchtern
TJT. W. Jax
T. W. Jax
MBM. K. Brenner
M. K. Brenner
A subset of stem cells, termed the “side population” (SP), has been identified in several tissues in mammalian species. These cells maintain a high efflux capability for antimitotic drugs. We have investigated whether functionally equivalent stem cells also may be detected in human cancers. We initially examined primary tumor cells from 23 patients with neuroblastoma and cell lines derived from a range of other tumors. A distinct SP was found in neuroblastoma cells from 15 of 23 patients (65%). The SP was capable of sustained expansion ex vivo and showed evidence for asymmetric division, generating both SP and non-SP progeny. These cells also expressed high levels of ABCG2 and ABCA3 transporter genes and had a greater capacity to expel cytotoxic drugs, such as mitoxantrone, resulting in better survival. A SP also was detected in breast cancer, lung cancer, and glioblastoma cell lines, suggesting that this phenotype defines a class of cancer stem cells with inherently high resistance to chemotherapeutic agents that should be targeted during the treatment of malignant disease.

10 June 2010 in Nature
Verified
Journal Article
Open access
PDF file
MBMegan Baldridge
Megan Baldridge
KKKatherine Y. King
Katherine Y. King
NBNathan C. Boles
Nathan C. Boles
DWDavid C. Weksberg
David C. Weksberg
MGMargaret A. Goodell
Margaret A. Goodell
Using a mouse model of bacterial infection, Baldridge et al. show that infection with Mycobacterium avium exerts a powerful stimulatory effect on haematopoietic stem cells, and that this stimulation is mediated by interferon-γ. Circulating immune cells in the blood are consumed during infection, and this work suggests that primitive stem cells in the marrow have a role in their replacement. These findings have implications for the use of interferon-γ as a therapeutic agent during chronic infections such as HIV/AIDS or tuberculosis and for recovery from bone marrow transplantation. Using a mouse model of Mycobacterium avium infection, it is shown here that interferon-γ regulates the proliferation of primitive haematopoietic cells during chronic infection. Lymphocytes and neutrophils are rapidly depleted by systemic infection1. Progenitor cells of the haematopoietic system, such as common myeloid progenitors and common lymphoid progenitors, increase the production of immune cells to restore and maintain homeostasis during chronic infection, but the contribution of haematopoietic stem cells (HSCs) to this process is largely unknown2. Here we show, using an in vivo mouse model of Mycobacterium avium infection, that an increased proportion of long-term repopulating HSCs proliferate during M. avium infection, and that this response requires interferon-γ (IFN-γ) but not interferon-α (IFN-α) signalling. Thus, the haematopoietic response to chronic bacterial infection involves the activation not only of intermediate blood progenitors but of long-term repopulating HSCs as well. IFN-γ is sufficient to promote long-term repopulating HSC proliferation in vivo; furthermore, HSCs from IFN-γ-deficient mice have a lower proliferative rate, indicating that baseline IFN-γ tone regulates HSC activity. These findings implicate IFN-γ both as a regulator of HSCs during homeostasis and under conditions of infectious stress. Our studies contribute to a deeper understanding of haematological responses in patients with chronic infections such as HIV/AIDS or tuberculosis3,4,5.